JPRN-jRCT2080222101未知2 期
A phase 2, multi-center, open-label, dose-finding trial to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of OPC-41061 in patients with chronic renal failure undergoing hemodialysis or hemodiafiltration
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •1)Patients with chronic renal failure who are undergoing hemodialysis or hemodiafiltration three times a week
- •2)Subjects between the ages of 20 and 80, inclusive (at time of informed consent)
- •3)Subjects who are inpatients or who can be admitted to the trial site for the duration of the trial period
- •4)Subjects who, together with their partner, are able to practice one of the specified contraceptive methods until 4 weeks after the final trial drug administration
- •5)Patients who are capable of providing written informed consent themselves before any trial-related procedures are performed
排除标准
- •1)Subjects with a complication of urinary impairment due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
- •2)Subject with daily urine volume less than 500 mL
- •3)Subject with Cardiac function of NYHA class 4
- •4)Subjects with serious ischemic heart disease, who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
- •5)Subjects with serious arrhythmia, who are judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
- •6)Subjects who are concomitantly undergoing peritoneal dialysis
- •7)Subjects with ascites due to cirrhosis or cancer, requring medical treatments
- •8)Subjects with any of the following medical histories:
- •- History of cerebrovascular disorder or coronary artery disease within 4 weeks prior to informed consent
- •- History of hypersensitivity or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride
- •9)Subjects with any of the following abnormal laboratory values:
- •- Hemoglobin lower than 8.0 g/dL, total bilirubin higher than 3.0 mg/dL, ALT (GPT) or AST (GOT) 2 times the upper limit of the reference range of the trial site, serum sodium higher than the upper limit of the reference range of the trial site, serum sodium lower than 125mEq/L
- •10)Subjects with serum potassium higher than 6.0mEq/L and abnormal findings inappropriate for inclusion in the trial are observed by 12-lead ECG
- •11)Subjects who are unable to sense thirst or who have difficulty with fluid or food intake
- •12)Subjects who have participated in any other clinical trial or post-marketing clinical studies within 4 weeks prior to informed consent
- •13)Female subjects who are pregnant, possibly pregnant, or nursing, or who plan to become pregnant during the trial period
- •14)Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the trial
研究者
相似试验
未知
2 期
Open-label dose-finding trial of OPC-41061 in patients with chronic renal failure undergoing peritoneal dialysisJPRN-jRCT2080222135Otsuka Pharmaceutical Co., Ltd.20
进行中（未招募）
1 期
clinical study for pediatric patients with solid tumors that have come back after disappearing or that don’t respond to any treatment, designed to find the safest and most tolerable dose of nab ®-paclitaxel and to asses the preliminary efficacy of the treatment.recurrent or refractory solid tumorMedDRA version: 14.1 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864EUCTR2013-000144-26-ITAbraxis BioScience, LLC, a wholly-owned subsidiary Celgene Corporation107
进行中（未招募）
1 期
clinical study for pediatric patients with solid tumors that have come back after disappearing or that don't respond to any treatment, designed to find the safest and most tolerable dose of nab®-paclitaxel and to asses the preliminary efficacy of the treatment.recurrent or refractory solid tumorMedDRA version: 14.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2013-000144-26-ESAbraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation105
进行中（未招募）
1 期
clinical study for pediatric patients with solid tumors that have come back after disappearing or that don’t respond to any treatment, designed to find the safest and most tolerable dose of nab ®-paclitaxel and to asses the preliminary efficacy of the treatment.EUCTR2013-000144-26-FRAbraxis BioScience, LLC, a wholly-owned subsidiary of Celgene Corporation107
进行中（未招募）
1 期
clinical study for pediatric patients with solid tumors that have come back after disappearing or that don’t respond to any treatment, designed to find the safest and most tolerable dose of nab ®-paclitaxel and to asses the preliminary efficacy of the treatment.recurrent or refractory solid tumorMedDRA version: 19.0 Level: LLT Classification code 10065147 Term: Malignant solid tumor System Organ Class: 100000004864EUCTR2013-000144-26-GBCelgene Corporation107